The US market for Hemostats and Sealants grew +6.4% YoY in Q219, a slightly lower growth rate vs Q119, with biologic sealants and thrombin hemostats driving the increase.
As reported in SmartTRAK’s Financial Dashboard, every manufacturer in the US Hemostats and Sealants market, except Ethicon, experienced revenue growth in Q219. Leading the way was Baxter, as it capitalized on Ethicon’s supply problems with Surgiflo. Cryolife and Becton Dickinson (BD) both posted strong gains. Ethicon still continued to dominate the overall US Hemostat and Sealants market, with a 40.7% share, down from 48.6% share in Q119. Most of this share shifted to Baxter as the Company continues to chip away at...
Among the many topics covered in the Q219 US Hemostats and Sealants Market Recap* are:
- Ethicon’s Market Dominance Slips
- Thrombin Hemostats Bounce Back Into Lead
- Biologic Sealants Surge Back To Growth
- Other Q219 US Hemostats and Sealants Market Events
BD’s relaunch of Progel led the resurgence of biologic sealants, which drove overall growth of the US Sealants market up +7.9% YoY.. After a one-quarter respite, thrombin hemostats again took the lead this quarter, contributing to the +5.5% YoY growth to...
*The entire article can only be viewed by SmartTRAK subscribers to this module. For information on how to subscribe, please click the button below.
